Clever is leaving the historic “Project Change Lives” initiative to provide US researchers with medical cannabis valued at US $ 25 million

Clever is leaving Holdings Inc. (NASDAQ: CLVR) announced the launch of its US-focused research initiative, Project change lives live, under which the company will donate up to $ 25 million in retail medical cannabis products to each eligible U.S. organization to advance scientific research into the potential medical benefits of cannabinoids.

The New York-based multinational cannabis operator announced Monday that it plans to provide up to 250,000 bottles of cannabis oils or about 5 tons of medicinal cannabis flowers free of charge to help researchers develop new therapies.

Clever Leaves works with that. together Biopharmaceutical research company, as a registered importer. The Biopharmaceutical Research Company holds federal licenses to import, analyze, and manufacture controlled substances.

The company, which plans to enter into this collaboration with US researchers immediately, will also sponsor a DNA sequencing study for its own cannabis strains.

“The US cannabis industry has experienced decades of research delays due to legal restrictions, on top of shortages in cannabis products or the lack of variety of high quality products, and the industry would benefit greatly from companies like Clever Leaves that offer affordable pharmaceutical products. high quality, EU GMP certified medical cannabis for research use, ”said Kyle Detwiler, CEO of Clever Leaves. “In addition to overcoming research hurdles, Project Change Lives hopes to create new opportunities for the advancement of medical treatments and access to patients by allowing legal cannabis ingredients and pharmaceuticals to travel freely across borders.”

“A nationwide appeal”

Clever Leaves also announced that it is launching a nationwide call for ideas and suggestions from academics and researchers at both universities and accredited institutions looking for medicinal cannabis for their research projects. Interested parties can apply at

The company cited several reasons why researchers would need its medicinal cannabis products:

  • Quality standards – the company has EU GMP certification, its growing practices are GACP certified and its medicinal cannabis extraction facility is said to be the only one in the world to have both Good Manufacturing Practices certifications from the European Union and INVIMA;
  • Sustainability practices;
  • Consistency and traceability services;
  • Technology and innovation activities;
  • Compliance with social responsibility protocols.

Price action

Clever Leaves’ shares were trading 2.76% lower at $ 10.58 per share at the time of writing.

Photo by Esteban Lopez on Unsplash

For the latest financial news, exclusive stories and memes, follow Benzinga on Twitter, Facebook and Instagram. For the best interviews, stock market talks and videos, subscribe to our YouTube channel.

© 2021 Benzinga does not offer investment advice. All rights reserved.

Source link

You May Also Like